PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Neoadjuvant chemotherapy with concurrent chemoradiotherapy in the treatment of nasopharyngeal cancer: Southern Tunisian experience.

Abstract A retrospective study to evaluate the efficacy and safety of the addition of neoadjuvant chemotherapy to concurrent chemoradiotherapy in the treatment of nasopharyngeal carcinoma.
PMID
Related Publications

Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3.

Evaluation of induction chemotherapy with vinorelbine plus cisplatin (NP) or docetaxel plus cisplatin (TP) combined with concurrent chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma.

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.

Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.

Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.

Authors

Mayor MeshTerms
Keywords

Cancer du nasopharynx

Chimiothérapie première

Nasopharyngeal carcinoma

Neoadjuvant chemotherapy

Radiotherapy

Radiothérapie

Journal Title bulletin du cancer
Publication Year Start




PMID- 29650393
OWN - NLM
STAT- MEDLINE
DCOM- 20180514
LR  - 20180514
IS  - 1769-6917 (Electronic)
IS  - 0007-4551 (Linking)
VI  - 105
IP  - 5
DP  - 2018 May
TI  - [Neoadjuvant chemotherapy with concurrent chemoradiotherapy in the treatment of
      nasopharyngeal cancer: Southern Tunisian experience].
PG  - 450-457
LID - S0007-4551(18)30077-8 [pii]
LID - 10.1016/j.bulcan.2018.02.004 [doi]
AB  - PURPOSE: A retrospective study to evaluate the efficacy and safety of the
      addition of neoadjuvant chemotherapy to concurrent chemoradiotherapy in the
      treatment of nasopharyngeal carcinoma. PATIENTS AND METHODS: Data from 62
      patients treated for non-metastatic nasopharyngeal carcinoma were analyzed by
      comparing two groups of patients: a first group of 32 patients treated with 3
      cycles of neoadjuvant chemotherapy based on docetaxel, cisplatin and
      5-fluoro-uracil every 21 days followed by concurrent chemoradiotherapy (weekly
      cisplatin 40mg/m(2) with radiotherapy 70Gy, 2Gy per session, 5 sessions per week)
      and a second group of 30 patients treated with the same concurrent
      chemoradiotherapy. RESULTS: After a median follow-up of 53.5 months, neoadjuvant 
      chemotherapy showed a significant reduction in the rate of a distant metastatic
      relapses (3.3% vs. 10%, P=0.03). No significant difference in disease-free
      survival at 5 years (65.6% vs. 68.8%, P=0.46) or overall survival at 5 years
      (68.8% vs. 73.3%, P=0.46) was noted between the two groups. Induction
      chemotherapy was associated with febrile neutropenia of 15.6%. During concurrent 
      chemoradiotherapy, hematological complications were greater in the first
      chemotherapy group (53% vs. 33%). CONCLUSION: Induction chemotherapy by
      docetaxel, cisplatin and 5-fluoro-uracil is a safe and effective option in the
      treatment of nasopharyngeal carcinoma. A better definition of high risk of
      relapse group would optimize the indications of this chemotherapy in the
      therapeutic arsenal.
CI  - Copyright (c) 2018 Societe Francaise du Cancer. Published by Elsevier Masson SAS.
      All rights reserved.
FAU - Mnejja, Wafa
AU  - Mnejja W
AD  - CHU Habib Bourguiba, service de radiotherapie carcinologique, Bourguiba route El 
      Ain km 1,5, 3000 Sfax, Tunisie.
FAU - Toumi, Nabil
AU  - Toumi N
AD  - CHU Habib Bourguiba, service de carcinologie medicale, Bourguiba route El Ain km 
      1,5, 3000 Sfax, Tunisie.
FAU - Fourati, Nejla
AU  - Fourati N
AD  - CHU Habib Bourguiba, service de radiotherapie carcinologique, Bourguiba route El 
      Ain km 1,5, 3000 Sfax, Tunisie. Electronic address: [email protected]
FAU - Bouzguenda, Racem
AU  - Bouzguenda R
AD  - CHU Habib Bourguiba, service de carcinologie medicale, Bourguiba route El Ain km 
      1,5, 3000 Sfax, Tunisie.
FAU - Ghorbel, Abdelmonem
AU  - Ghorbel A
AD  - CHU Habib Bourguiba, service ORL, Bourguiba route El Ain km 1,5, 3000 Sfax,
      Tunisie.
FAU - Frikha, Mounir
AU  - Frikha M
AD  - CHU Habib Bourguiba, service de carcinologie medicale, Bourguiba route El Ain km 
      1,5, 3000 Sfax, Tunisie.
FAU - Siala, Wicem
AU  - Siala W
AD  - CHU Habib Bourguiba, service de radiotherapie carcinologique, Bourguiba route El 
      Ain km 1,5, 3000 Sfax, Tunisie.
FAU - Daoud, Jamel
AU  - Daoud J
AD  - CHU Habib Bourguiba, service de radiotherapie carcinologique, Bourguiba route El 
      Ain km 1,5, 3000 Sfax, Tunisie.
LA  - fre
PT  - Comparative Study
PT  - Journal Article
TT  - La chimiotherapie neoadjuvante associee a la chimioradiotherapie concomitante
      dans le traitement du cancer du nasopharynx : experience du Sud-Tunisien.
DEP - 20180409
PL  - France
TA  - Bull Cancer
JT  - Bulletin du cancer
JID - 0072416
RN  - 0 (Taxoids)
RN  - 15H5577CQD (docetaxel)
RN  - Q20Q21Q62J (Cisplatin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Chemoradiotherapy/adverse effects/mortality
MH  - Chemotherapy, Adjuvant/adverse effects/mortality
MH  - Cisplatin/administration & dosage
MH  - Female
MH  - Fluorouracil/administration & dosage
MH  - Humans
MH  - Induction Chemotherapy/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Nasopharyngeal Neoplasms/mortality/pathology/*therapy
MH  - Neoplasm Recurrence, Local/prevention & control
MH  - Neutropenia/chemically induced
MH  - Radiotherapy Dosage
MH  - Retrospective Studies
MH  - Taxoids/administration & dosage
MH  - Tunisia
OTO - NOTNLM
OT  - Cancer du nasopharynx
OT  - Chimiotherapie premiere
OT  - Nasopharyngeal carcinoma
OT  - Neoadjuvant chemotherapy
OT  - Radiotherapy
OT  - Radiotherapie
EDAT- 2018/04/14 06:00
MHDA- 2018/05/15 06:00
CRDT- 2018/04/14 06:00
PHST- 2017/11/14 00:00 [received]
PHST- 2018/01/15 00:00 [revised]
PHST- 2018/02/13 00:00 [accepted]
PHST- 2018/04/14 06:00 [pubmed]
PHST- 2018/05/15 06:00 [medline]
PHST- 2018/04/14 06:00 [entrez]
AID - S0007-4551(18)30077-8 [pii]
AID - 10.1016/j.bulcan.2018.02.004 [doi]
PST - ppublish
SO  - Bull Cancer. 2018 May;105(5):450-457. doi: 10.1016/j.bulcan.2018.02.004. Epub
      2018 Apr 9.